HOLD YOUR SHARES! The best is yet to come!
-Already acquired Patents in EU and Hong Kong for Lumega-Z and MapCatSF device.
-Chinese/India patent news for the Lumega-Z and GlaucoCetin would send the stock flying (check previous spikes)
-Chinese trademark secured, Chinese entity owns 5% ownership stake, lets see what happens!
-Last offering was direct offering and closed within 24 hours. Meaning we have a solid 30% or more institutional holding now. Which will be disclosed before Sept. 30th
-International sales distribution agreement imminent
-Amazon or Alibaba sales channel could give us an NBY type move
-AREDS-2 (leading competitor) is featured on Amazon, Lumega-Z is a better product backed by clinical research
-CSV-2000 pending military contracts
-World class management team and medical professionals
-Massive gap to fill
-At $1.50/sh the market cap is only $54M!
-Glaucoma market is massive world wide, Chinese market alone is 22M patients
-Only for US and China markets we have more than 80 thousand ophthalmologist. CSV-2000 Cost $7500/- Think even 10% penetration means what to them in terms of revenue from a single product.
-Patent portfolio worth more than current market cap
-Insider lock up period ended, every incentive to pump the price
-The company did not IPO in April to get delisted 6 months later
-Adequate cash from offering, no dilution imminent
AI
